About cardiff oncology - CRDF
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
CRDF At a Glance
Cardiff Oncology, Inc.
11055 Flintkote Avenue
San Diego, California 92121
| Phone | 1-858-952-7570 | Revenue | 683.00K | |
| Industry | Medical Specialties | Net Income | -45,431,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 39.959% | |
| Fiscal Year-end | 12 / 2025 | Employees | 33 | |
| View SEC Filings |
CRDF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 302.783 |
| Price to Book Ratio | 3.481 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.416 |
| Enterprise Value to Sales | 170.685 |
| Total Debt to Enterprise Value | 0.013 |
CRDF Efficiency
| Revenue/Employee | 20,696.97 |
| Income Per Employee | -1,376,696.97 |
| Receivables Turnover | 0.582 |
| Total Asset Turnover | 0.008 |
CRDF Liquidity
| Current Ratio | 7.079 |
| Quick Ratio | 7.079 |
| Cash Ratio | 6.832 |
CRDF Profitability
| Gross Margin | 40.849 |
| Operating Margin | -7,123.133 |
| Pretax Margin | -6,651.684 |
| Net Margin | -6,651.684 |
| Return on Assets | -50.81 |
| Return on Equity | -59.508 |
| Return on Total Capital | -53.782 |
| Return on Invested Capital | -58.636 |
CRDF Capital Structure
| Total Debt to Total Equity | 1.836 |
| Total Debt to Total Capital | 1.803 |
| Total Debt to Total Assets | 1.567 |
| Long-Term Debt to Equity | 0.98 |
| Long-Term Debt to Total Capital | 0.962 |